聚乙二醇脂质体阿霉素与托泊替康治疗复发难治性卵巢上皮癌患者的长期生存优势比较:3期随机研究

聚乙二醇脂质体阿霉素与托泊替康治疗复发难治性卵巢上皮癌患者的长期生存优势比较：3期随机研究
Gordon A.N.;Tonda M.;Rackoff W.;张剑萍
【期刊名称】《世界核心医学期刊文摘：妇产科学分册》
【年(卷),期】2005(000)002
【摘要】Provide long -term follow -up data fo r women treated in a randomized multicenter study of pegylated liposomal dox-orubicin compared with topotecan.P atients with epithelial ovarian cancer that recurred after o r failed to respond to firstline platinum -based chemotherapy were randomized to receive pegylated liposomal doxoru bicin 50mg /m 2 every28days(n =239)or topotecan 1.5mg /m 2 per day for 5days every 21days(n =235).Patients were stratified prospectively based on response to i nitial platinum -based chemotherapy as well as the presence or absence of bulky disease.Most patients had been previously treated with platinum and taxanes(74%in the pegylated liposomal doxorubicin group and 72%in the topotecan group).Survival data are mature:87%of patients have died(n =413).There was an 18%reduction in the ris k of death for patients treated with pegy lated liposomal doxoru-bicin(median survival 62.7weeks for pegylated liposomal doxorubicin and 59.7weeks for topotecan -treated pa-tients;HR =1.216;95%confidence in terval(CI )1.000-1.478;P =0.050).The hazard ratio for all randomized subjects(includes those randomized,but never treated;n =481)was 1.23(median survival 63.6weeks
for pegylated liposomal doxorubicin and 57.0weeks for topotecan -treated patients;95%CI 1.01-1.50;P =0.038).For patients with platinum -sensitive
dis-ease,there was a 30%reduction in the risk of death for the pegylated liposomal doxorubicin -t reated group(median survival 107.9weeks for pegylated l iposomal doxorubicin and 70.1weeks for topotecan -treate d patients;HR =1.432;95%CI 1.066-1.923;P =0.017).In pa-tients with platinum -refractory di sease,survival was similar between treatment groups.L ong -term follow -up demonstrates that treatmentwith pegylated liposomal
dox-orubicin significantly prolongs su rvival compared with topotecan in patients with recurren t and refractory epithelial ovarian cancer.The survival benefi t is pronounced in pa-tients with platinumsensitive dise ase.【总页数】1页(P42-42)
【作者】Gordon A.N.;Tonda M.;Rackoff W.;张剑萍
【作者单位】
【正文语种】中文
【中图分类】R737.31
【相关文献】
1.替莫唑胺联合托泊替康治疗儿童难治性/复发神经母细胞瘤6例临床分析 [J], 李梅;张语桐;钟晓丹;王立哲;金仙梅;常健
2.拓扑替康1次/周治疗难治性复发性卵巢上皮癌的效果[J], O’ Malley
D.M.;Azodi M.;Makkenchery A.;张丽娟
3.托泊替康及卡铂治疗潜伏性铂敏感的复发性卵巢及腹膜癌的Ⅰ/Ⅱ期临床试验 [J],
Rose P.G.;Smrekar M.;Haba P.;朱晓明
4.三维适形放疗联合托泊替康化疗治疗铂类耐药复发卵巢上皮癌的临床疗效 [J], 刘红岩;张丽敏;冯紫薇;王磊
5.聚乙二醇化脂质体阿霉素治疗复发性卵巢癌的中国专家共识 [J], 马丁;沈铿;谢幸;孔北华
因版权原因，仅展示原文概要，查看原文内容请购买。